The Times of India reported that Google DeepMind is utilizing its Gemini AI model to handle 40% to 50% of legal information requests, enhancing efficiency in the company’s operations. Terra Terwilliger, Google DeepMind’s director of strategic initiatives, highlighted the AI’s role in managing routine tasks, allowing employees to focus on higher-value work. Terwilliger emphasized how AI assists in retrieving information quickly, saving time for the legal department.
At the same event, Sebastian Guth, COO of Bayer’s pharmaceuticals division, revealed that AI manages 70% to 80% of their regulatory filings for drug development. Both companies stress that AI is enhancing processes without displacing human workers.
Terwilliger pointed out the necessity of training employees to use AI tools effectively. “It’s important to value the time spent learning these systems,” she explained, underscoring that AI implementation focuses on efficiency rather than workforce reduction. Echoing this sentiment, Guth remarked that technology, particularly AI, must serve a purpose—like accelerating drug development—rather than just being used for the sake of innovation.
Both examples demonstrate how AI, including DeepMind’s Gemini model, is increasingly integrated into corporate workflows, but always with the aim of optimizing rather than replacing human roles.
